Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Lenvenib 4mg Tablets | 105-Count | LENVATINIB
Pharma

Lenvenib 4mg Tablets | 105-Count | LENVATINIB

$370

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

India Warehouse LENVATINIB — 4mg per tablet, 105-count pack. Multi-kinase inhibitor for differentiated thyroid cancer, hepatocellular carcinoma (HCC), endometrial carcinoma (with pembrolizumab), and renal cell carcinoma. Key warning: Blood pressure monitoring from day 1. Hepatotoxicity monitoring. Hold 1 week before surgery. Embryofetal toxicity. QT prolongation monitoring.

SKU
VES-002168-LENVENIB-4MG-105TAB
Format
N/A
Use
Laboratory research only
Ask on Telegram

What is Lenvenib 4mg (LENVATINIB)?

Multi-kinase inhibitor for differentiated thyroid cancer, hepatocellular carcinoma (HCC), endometrial carcinoma (with pembrolizumab), and renal cell carcinoma.

How it Works

Inhibits VEGFR1-3, FGFR1-4, PDGFRalpha, KIT, and RET kinases — broadly blocks tumor angiogenesis and proliferative signaling.

Quick Specs

Form
Oral tablets — pre-dosed
Active Ingredient
LENVATINIB
Dose per Tablet
4MG
Pack Size
105 tablets
Storage
Room temperature (15–25°C), cool dry place
Shelf Life
2–3 years (properly stored)

Common Side Effects

Hypertension (very common), fatigue, diarrhea, decreased appetite, nausea, hand-foot syndrome, proteinuria, hepatotoxicity.

Safety Warnings

Blood pressure monitoring from day 1. Hepatotoxicity monitoring. Hold 1 week before surgery. Embryofetal toxicity. QT prolongation monitoring. International shipping: 7–14 days

Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.